Clinical outcomes reveal Ivosidenib monotherapy achieves CR/CRi rates of 63% and 72% respectively, in IDH1-mutated R/R AML, with an estimated 1-year OS of 76%–78% (Stein et al., 2021). Here, IDH1 is linked to acute myeloid leukemia.